CTOs on the Move

Oncopeptides

www.oncopeptides.com

 
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Bio-Boiler Systems Inc

Bio-Boiler Systems Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Comfort Medical

You will find the best source for major brands and most types of catheter and ostomy supplies at Comfort Medical. Free Home Delivery 800-700-4246

Life Science Services International

Life Science Services International is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alliance Health

Alliance Health is an innovative technology company whose mission is to improve health outcomes, lower costs and foster a more consumer-centric healthcare industry. We own and operate the internet`s largest group of condition-specific social communities serving over 1.5 million registered members across a broad set of chronic health conditions. Each site leverages social and mobile elements to empower patients and caregivers with connections to supportive peers, personalized information, and relevant products and services. We also offer access to affordable prescription medications, either home-delivered, or through our pharmacy network.

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.